An insight into the mechanisms of action of selected bioactive compounds against epigenetic targets of prostate cancer: implications on histones modifications

[1]  Julia Kallenbach,et al.  Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer , 2022, Cell & bioscience.

[2]  M. Chopra,et al.  HDAC6: A unique HDAC family member as a cancer target , 2022, Cellular Oncology.

[3]  Youqing Wang,et al.  Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019 , 2022, Frontiers in Public Health.

[4]  Xiaoqi Liu,et al.  Epigenetics in prostate cancer treatment , 2021, Journal of translational genetics and genomics.

[5]  E. Chokunonga,et al.  Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study , 2021, Cancer Causes & Control.

[6]  M. Nakanishi,et al.  Navigating the DNA methylation landscape of cancer. , 2021, Trends in genetics : TIG.

[7]  L. Altucci,et al.  Epigenetic mechanisms underlying prostate cancer radioresistance , 2021, Clinical epigenetics.

[8]  H. Beltran,et al.  Epigenetics in prostate cancer: clinical implications , 2021, Translational andrology and urology.

[9]  G. Zadra,et al.  Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer , 2021, Cancer drug resistance.

[10]  A. Alexiou,et al.  Zinc Metalloproteins in Epigenetics and Their Crosstalk , 2021, Life.

[11]  P. Østergren,et al.  Neglected side effects to curative prostate cancer treatments , 2020, International Journal of Impotence Research.

[12]  I. Malami,et al.  In silico predictions on the possible mechanism of action of selected bioactive compounds against breast cancer , 2020, In silico pharmacology.

[13]  A. Kaneda,et al.  Epigenetic modifications in prostate cancer , 2020, International journal of urology : official journal of the Japanese Urological Association.

[14]  D. Parkin,et al.  Rising Prostate Cancer Incidence in Sub-Saharan Africa: A Trend Analysis of Data from the African Cancer Registry Network , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[15]  M. Farzaei,et al.  Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach , 2020, Cancers.

[16]  Jian Lu,et al.  New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases , 2019, Acta pharmaceutica Sinica. B.

[17]  Chen-Yang Jia,et al.  A drug-likeness toolbox facilitates ADMET study in drug discovery. , 2019, Drug discovery today.

[18]  Yuan Xu,et al.  Synthesis, in vitro assays, molecular docking, theoretical ADMET prediction, and evaluation of 4-methoxy-phenylthiazole-2-amine derivatives as acetylcholinesterase inhibitors , 2019, Medicinal Chemistry Research.

[19]  Smita C. Pawar,et al.  Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer , 2019, Oxidative medicine and cellular longevity.

[20]  S. Verdura,et al.  Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers , 2019, International journal of molecular sciences.

[21]  Edmund Chiong,et al.  The incidence, mortality, and risk factors of prostate cancer in Asian men , 2018, Prostate international.

[22]  F. Sánchez‐Madrid,et al.  HDAC6 at Crossroads of Infection and Innate Immunity. , 2018, Trends in immunology.

[23]  Dong-Sheng Cao,et al.  ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database , 2018, Journal of Cheminformatics.

[24]  N. Ahmad,et al.  Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications. , 2018, Cancer letters.

[25]  D. Fedida,et al.  Probing the molecular basis of hERG drug block with unnatural amino acids , 2018, Scientific Reports.

[26]  K. Lam,et al.  Combinatorial chemistry in drug discovery. , 2017, Current opinion in chemical biology.

[27]  R. Franco,et al.  A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma , 2016, Molecules.

[28]  G. Packham,et al.  Epigenetic modulators as therapeutic targets in prostate cancer , 2016, Clinical Epigenetics.

[29]  Hyeonseok Ko,et al.  Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells , 2016, Oncotarget.

[30]  Dan Li,et al.  The application of in silico drug-likeness predictions in pharmaceutical research. , 2015, Advanced drug delivery reviews.

[31]  Iskander Yusof,et al.  Considering the impact drug-like properties have on the chance of success. , 2013, Drug discovery today.

[32]  S. Harriman,et al.  Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). , 2013, Drug discovery today. Technologies.

[33]  David E. Williams,et al.  3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. , 2012, Toxicology and applied pharmacology.

[34]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[35]  J. Alumkal,et al.  Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6 , 2009, Proceedings of the National Academy of Sciences.

[36]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[37]  J. Batra,et al.  Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. , 2021, American journal of cancer research.

[38]  A. Mazumder,et al.  4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer. , 2016, Biochemical pharmacology.